Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


18.04.2017

1 Clin Infect Dis
1 Eur J Gastroenterol Hepatol
1 Gastroenterology
2 Hepatology
3 J Hepatol
1 J Infect Dis
4 J Med Virol
1 J Virol
29 Lancet Gastroenterol Hepatol
1 Pediatr Infect Dis J
7 PLoS One
1 PLoS Pathog
1 Proc Natl Acad Sci U S A
1 Transplant Proc
1 Vaccine
1 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Clin Infect Dis

  1. CANARY L, Hariri S, Campbell C, Young R, et al
    Geographic disparities in access to syringe services programs among young people with hepatitis C virus infection in the U.S.
    Clin Infect Dis. 2017 Apr 11. doi: 10.1093.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  2. TABERNILLA A, Grandal M, Pernas B, Castro-Iglesias A, et al
    Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Eur J Gastroenterol Hepatol. 2017 Apr 13. doi: 10.1097/MEG.0000000000000882.
    PubMed     Text format     Abstract available


    Gastroenterology

  3. JACOBSON IM, Lawitz E, Gane EJ, Willems BE, et al
    Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Gastroenterology. 2017 Apr 5. pii: S0016-5085(17)35399.
    PubMed     Text format     Abstract available


    Hepatology

  4. GUO X, Wang S, Qiu ZG, Dou YL, et al
    Efficient replication of blood borne Hepatitis C Virus in human fetal liver stem cells.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29211.
    PubMed     Text format     Abstract available

  5. ONO A, Goossens N, Finn RS, Schmidt WN, et al
    Persisting risk of hepatocellular carcinoma after HCV cure monitored by a liver transcriptome signature.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29203.
    PubMed     Text format    


    J Hepatol

  6. SCHWARZINGER M, Baillot S, Yazdanpanah PY, Rehm PJ, et al
    Contribution of Alcohol Use Disorders on the Burden of Chronic Hepatitis C in France, 2008-2013: A Nationwide Retrospective Cohort Study.
    J Hepatol. 2017 Apr 7. pii: S0168-8278(17)30202.
    PubMed     Text format     Abstract available

  7. LANGHANS B
    Reply to "In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals".
    J Hepatol. 2017 Apr 9. pii: S0168-8278(17)30205.
    PubMed     Text format    

  8. SHIRVANI-DASTGERDI E, Winer BY, Celia-Terrassa A, Kang Y, et al
    Selection of the highly replicative and partially multidrug resistant rtS78T polymerase mutation in two patients with chronic hepatitis B virus infection during tenofovir-entecavir combination therapy.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30198.
    PubMed     Text format     Abstract available


    J Infect Dis

  9. LI D, Wang X, von Schaewen M, Tao W, et al
    Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Med Virol

  10. JIAO X, Fan Z, Chen H, He P, et al
    Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24829.
    PubMed     Text format     Abstract available

  11. DE PASCHALE M, Manco MT, Arpino O, Ricucci V, et al
    Threshold value of LIAISON XL anti-HCV screening assay predicting positive immunoblotting results.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24831.
    PubMed     Text format     Abstract available

  12. WANG J, Zhang H, Zhang Y, Jiang D, et al
    Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24830.
    PubMed     Text format     Abstract available

  13. EL-MOWAFY M, Elgaml A, El-Mesery M, Elegezy M, et al
    Molecular analysis of Hepatitis B virus sub-genotypes and incidence of preS1/preS2 region mutations in HBV-infected Egyptian patients from Mansoura.
    J Med Virol. 2017 Apr 8. doi: 10.1002/jmv.24828.
    PubMed     Text format     Abstract available


    J Virol

  14. FAN H, Qiao L, Kang KD, Fan J, et al
    Attachment and Post-Attachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.
    J Virol. 2017 Apr 12. pii: JVI.00280-17. doi: 10.1128/JVI.00280.
    PubMed     Text format     Abstract available


    Lancet Gastroenterol Hepatol

  15. THE LANCET GASTROENTEROLOGY HE
    Access to HCV treatments: hurdles not barriers.
    Lancet Gastroenterol Hepatol. 2017;2:1.
    PubMed     Text format    

  16. DEBES JD, Janssen HL, Boonstra A
    Hepatitis C treatment and liver cancer recurrence: cause for concern?
    Lancet Gastroenterol Hepatol. 2017;2:78-80.
    PubMed     Text format    

  17. ROCKSTROH JK, Bhagani S, Hyland RH, Yun C, et al
    Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
    Lancet Gastroenterol Hepatol. 2017;2:347-353.
    PubMed     Text format     Abstract available


  18. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    Lancet Gastroenterol Hepatol. 2017;2:325-336.
    PubMed     Text format     Abstract available

  19. MARTINELLO M, Grebely J, Matthews GV
    Direct-acting antivirals for acute HCV: how short can we go?
    Lancet Gastroenterol Hepatol. 2017;2:316-318.
    PubMed     Text format    

  20. DUSHEIKO G
    Hepatitis C in the EU: setting the terms for elimination.
    Lancet Gastroenterol Hepatol. 2017;2:314-315.
    PubMed     Text format    

  21. THE LANCET GASTROENTEROLOGY HE
    Viral hepatitis: will expanded screening measures pass the test?
    Lancet Gastroenterol Hepatol. 2017;2:313.
    PubMed     Text format    

  22. LIM SG, Aghemo A, Chen PJ, Dan YY, et al
    Management of hepatitis C virus infection in the Asia-Pacific region: an update.
    Lancet Gastroenterol Hepatol. 2017;2:52-62.
    PubMed     Text format     Abstract available

  23. YOUNOSSI ZM, Stepanova M, Charlton M, Curry MP, et al
    Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Lancet Gastroenterol Hepatol. 2016;1:122-132.
    PubMed     Text format     Abstract available

  24. INGILIZ P, Rockstroh JK
    Hepatitis C virus reinfection-more to come?
    Lancet Gastroenterol Hepatol. 2017;2:150-151.
    PubMed     Text format    

  25. CIGLENECKI I
    Hepatitis E: urgent action needed.
    Lancet Gastroenterol Hepatol. 2017;2:154.
    PubMed     Text format    

  26. KAMAR N, Wang W, Dalton HR, Pan Q, et al
    Direct-acting antiviral therapy for hepatitis E virus?
    Lancet Gastroenterol Hepatol. 2017;2:154-155.
    PubMed     Text format    

  27. COOPER S, Umeweni N, Knight H, McVeigh G, et al
    Sofosbuvir-velpatasvir for treating chronic hepatitis C.
    Lancet Gastroenterol Hepatol. 2017;2:156-157.
    PubMed     Text format    


  28. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
    Lancet Gastroenterol Hepatol. 2017;2:161-176.
    PubMed     Text format     Abstract available

  29. BOURLIERE M, Rabiega P, Ganne-Carrie N, Serfaty L, et al
    Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepat
    Lancet Gastroenterol Hepatol. 2017;2:177-188.
    PubMed     Text format     Abstract available

  30. ISLAM N, Krajden M, Shoveller J, Gustafson P, et al
    Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
    Lancet Gastroenterol Hepatol. 2017;2:200-210.
    PubMed     Text format     Abstract available

  31. THE LANCET GASTROENTEROLOGY HE
    Hepatitis E: a neglected virus.
    Lancet Gastroenterol Hepatol. 2016;1:261.
    PubMed     Text format    

  32. HAJARIZADEH B, Grebely J, Martinello M, Matthews GV, et al
    Hepatitis C treatment as prevention: evidence, feasibility, and challenges.
    Lancet Gastroenterol Hepatol. 2016;1:317-327.
    PubMed     Text format     Abstract available

  33. FOSTER GR
    Chronic hepatitis C: less of a problem than first thought?
    Lancet Gastroenterol Hepatol. 2017;2:146-147.
    PubMed     Text format    

  34. WAKED I, Shiha G, Qaqish RB, Esmat G, et al
    Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
    Lancet Gastroenterol Hepatol. 2016;1:36-44.
    PubMed     Text format     Abstract available

  35. COILLY A, Roche B, Duclos-Vallee JC, Samuel D, et al
    Optimum timing of treatment for hepatitis C infection relative to liver transplantation.
    Lancet Gastroenterol Hepatol. 2016;1:165-172.
    PubMed     Text format     Abstract available

  36. CORNBERG M, Manns MP
    Hepatitis C: individualised medicine versus one pill fits all.
    Lancet Gastroenterol Hepatol. 2016;1:86-87.
    PubMed     Text format    

  37. BUTI M, Esteban R
    Patient experience in HCV therapy: what really matters.
    Lancet Gastroenterol Hepatol. 2016;1:90-92.
    PubMed     Text format    

  38. BROUWER WP
    Tenofovir alafenamide for hepatitis B: evolution or revolution?
    Lancet Gastroenterol Hepatol. 2016;1:174-175.
    PubMed     Text format    

  39. CHAN HL, Fung S, Seto WK, Chuang WL, et al
    Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    Lancet Gastroenterol Hepatol. 2016;1:185-195.
    PubMed     Text format     Abstract available

  40. BUTI M, Gane E, Seto WK, Chan HL, et al
    Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
    Lancet Gastroenterol Hepatol. 2016;1:196-206.
    PubMed     Text format     Abstract available

  41. WAIT S, Kell E, Hamid S, Muljono DH, et al
    Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments.
    Lancet Gastroenterol Hepatol. 2016;1:248-255.
    PubMed     Text format     Abstract available

  42. ASSELAH T, Hezode C, Qaqish RB, ElKhashab M, et al
    Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
    Lancet Gastroenterol Hepatol. 2016;1:25-35.
    PubMed     Text format     Abstract available

  43. RYDER S, Pett S, Cooke GS
    Genotype 4 and the global challenge of hepatitis C treatment.
    Lancet Gastroenterol Hepatol. 2016;1:3-4.
    PubMed     Text format    


    Pediatr Infect Dis J

  44. MAJEKODUNMI AO, Thorne C, Malyuta R, Volokha A, et al
    Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy.
    Pediatr Infect Dis J. 2017;36:e123-e129.
    PubMed     Text format     Abstract available


    PLoS One

  45. NGUYEN HM, Sy BT, Trung NT, Hoan NX, et al
    Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam.
    PLoS One. 2017;12:e0175304.
    PubMed     Text format     Abstract available

  46. CHLIBEK R, Smetana J, Sosovickova R, Gal P, et al
    Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.
    PLoS One. 2017;12:e0175525.
    PubMed     Text format     Abstract available

  47. YANG CM, Yoon JC, Park JH, Lee JM, et al
    Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
    PLoS One. 2017;12:e0175793.
    PubMed     Text format     Abstract available

  48. FERNANDEZ-CABALLERO JA, Alvarez M, Chueca N, Perez AB, et al
    The cobas(R) HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice.
    PLoS One. 2017;12:e0175564.
    PubMed     Text format     Abstract available

  49. LE GUILLOU-GUILLEMETTE H, Pivert A, Bouthry E, Henquell C, et al
    Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma.
    PLoS One. 2017;12:e0174651.
    PubMed     Text format     Abstract available

  50. YASUI Y, Abe T, Kurosaki M, Higuchi M, et al
    Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma.
    PLoS One. 2016;11:e0154558.
    PubMed     Text format     Abstract available

  51. DU H, Yang J, Bai J, Ming K, et al
    A flavone-polysaccharide based prescription attenuates the mitochondrial dysfunction induced by duck hepatitis A virus type 1.
    PLoS One. 2017;12:e0175495.
    PubMed     Text format     Abstract available


    PLoS Pathog

  52. LIU Y, Nie H, Mao R, Mitra B, et al
    Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA.
    PLoS Pathog. 2017;13:e1006296.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  53. HANSEN MD, Johnsen IB, Stiberg KA, Sherstova T, et al
    Hepatitis C virus triggers Golgi fragmentation and autophagy through the immunity-related GTPase M.
    Proc Natl Acad Sci U S A. 2017 Apr 7. pii: 201616683.
    PubMed     Text format     Abstract available


    Transplant Proc

  54. SAFWAN M, Nagai S, Abouljoud MS
    Portal Vein Inflow From Enlarged Coronary Vein in Liver Transplantation: Surgical Approach and Technical Tips: A Case Report.
    Transplant Proc. 2016;48:3070-3072.
    PubMed     Text format     Abstract available


    Vaccine

  55. JIANG HY, Wang SY, Deng M, Li YC, et al
    Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis.
    Vaccine. 2017 Apr 9. pii: S0264-410X(17)30432.
    PubMed     Text format     Abstract available


    Virology

  56. EYRE NS, Aloia AL, Joyce MA, Chulanetra M, et al
    Sensitive luminescent reporter viruses reveal appreciable release of hepatitis C virus NS5A protein into the extracellular environment.
    Virology. 2017;507:20-31.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: